Resultados de búsqueda - David Russell‐Jones

Limitar resultados
  1. 1
    Recent advances in incretin‐based therapies

    Recent advances in incretin‐based therapies por David Russell‐Jones, Stephen Gough

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Growth hormone and sport: abuse, potential benefits, and difficulties in detection.

    Growth hormone and sport: abuse, potential benefits, and difficulties in detection. por Marie Louise Healy, David Russell‐Jones

    Publicado 1997
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  3. 3
    Identification of barriers to insulin therapy and approaches to overcoming them

    Identification of barriers to insulin therapy and approaches to overcoming them por David Russell‐Jones, Frans Pouwer, Kamlesh Khunti

    Publicado 2017
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  4. 4
    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men

    Effects of three weeks of mild sleep restriction implemented in the home environment on multiple metabolic and endocrine markers in healthy young men por M. Denise Robertson, David Russell‐Jones, A. Margot Umpleby, Derk‐Jan Dijk

    Publicado 2012
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Insulin X10 revisited: a super-mitogenic insulin analogue

    Insulin X10 revisited: a super-mitogenic insulin analogue por Bent Hansen, Peter Kurtzhals, Astrid B. Jensen, A. Dejgaard, David Russell‐Jones

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  6. 6
    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials

    Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials por David Russell‐Jones, M.‐A. Gall, M. Niemeyer, M. Diamant, Stefano Del Prato

    Publicado 2015
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  7. 7
    Miscoding, misclassification and misdiagnosis of diabetes in primary care

    Miscoding, misclassification and misdiagnosis of diabetes in primary care por Simon de Lusignan, Norah Hassan Sadek, Henrietta Mulnier, Aumran Tahir, David Russell‐Jones, Kamlesh Khunti

    Publicado 2011
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

    Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp por S. V. M. Hordern, Jonelle E. Wright, A. Margot Umpleby, Fariba Shojaee‐Moradie, J. Amiss, David Russell‐Jones

    Publicado 2005
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes

    High Dose Growth Hormone Exerts an Anabolic Effect at Rest and during Exercise in Endurance-Trained Athletes por Marie Louise Healy, James Gibney, David Russell‐Jones, Claire Pentecost, P Croos, P H Sönksen, A. Margot Umpleby

    Publicado 2003
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

    Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial por David Russell‐Jones, Allan Vaag, O. Schmitz, Bipin Sethi, Nebojša Lalić, Slobodan Antić, Marija Zdravković, Gabriela Martinez Ravn, Rafael Simó

    Publicado 2009
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial

    Efficacy and safety of fast‐acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52‐week, randomized, treat‐to‐target, phase III trial por Chantal Mathieu, Bruce W. Bode, Edward Franek, Athena Philis‐Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell‐Jones

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes

    Rationale and design of the phase 3a development programme (<scp>ONWARDS</scp> 1–6 trials) investigating once‐weekly insulin icodec in diabetes por Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  13. 13
    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome

    Insulin-Sensitizing Effects on Muscle and Adipose Tissue after Dietary Fiber Intake in Men and Women with Metabolic Syndrome por M. Denise Robertson, John W. Wright, Emmanuelle Loizon, Cyrille Debard, Hubert Vidal, Fariba Shojaee‐Moradie, David Russell‐Jones, A. Margot Umpleby

    Publicado 2012
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  14. 14
    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

    Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) por David Russell‐Jones, Robert Cuddihy, M Hanefeld, Ajay Kumar, José Gerardo González‐González, Melanie Chan, Anne M. Wolka, Marilyn K. Boardman

    Publicado 2011
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  15. 15
    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes

    Insulin-Like Growth Factor I Has a Direct Effect on Glucose and Protein Metabolism, But No Effect on Lipid Metabolism in Type 1 Diabetes por Helen Simpson, Nicola Jackson, Fariba Shojaee‐Moradie, R. H. Jones, David Russell‐Jones, Peter H. Sönksen, David B. Dunger, A. Margot Umpleby

    Publicado 2004
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  16. 16
    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK

    Characteristics and outcomes of patients with COVID-19 at a district general hospital in Surrey, UK por Harry Knights, Nikhil Mayor, Kristina Millar, Matthew Cox, Evgeniya Bunova, Morgan Hughes, Jack W. Baker, Sanju Mathew, David Russell‐Jones, Aleksandra Kotwica

    Publicado 2020
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  17. 17
    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension

    Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Tr... por Chantal Mathieu, Priscilla Hollander, Bresta Miranda-Palma, John Cooper, Edward Franek, David Russell‐Jones, J. B. Larsen, Søren C. Tamer, Stephen C. Bain

    Publicado 2013
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  18. 18
    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial

    Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label,... por David Russell‐Jones, Tetsuya Babazono, Roman Cailleteau, Susanne Engberg, Concetta Irace, Maiken Ina Siegismund Kjaersgaard, Chantal Mathieu, Julio Rosenstock, Vincent Woo, David C. Klonoff

    Publicado 2023
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  19. 19
    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes

    Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes por Philip Home, Paul B. Bartley, David Russell‐Jones, H Hanaire-Broutin, Jan‐Evert Heeg, Pascale Abrams, Mona Landin–Olsson, Birgitte Hylleberg, Hanne Lang, Eberhard Draeger

    Publicado 2004
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  20. 20
    Efficacy of increased resistant starch consumption in human type 2 diabetes

    Efficacy of increased resistant starch consumption in human type 2 diabetes por Caroline L. Bodinham, Lee Smith, E. Louise Thomas, Jimmy D. Bell, Jonathan R. Swann, Adele Costabile, David Russell‐Jones, A. Margot Umpleby, M. Denise Robertson

    Publicado 2014
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: